Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
Conmed Corporation (CNMD) delivers innovative medical technologies that enhance surgical outcomes and patient care worldwide. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, financial performance, and product advancements shaping the medical device sector.
Access authoritative information on CNMD's latest earnings reports, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing new product launches in orthopedics, general surgery, and patient monitoring systems, along with updates on global market expansion initiatives.
Stay informed about critical developments through verified announcements directly from Conmed Corporation and third-party analysis. This resource enables stakeholders to track the company's progress in advancing minimally invasive surgical techniques and improving clinical workflows across healthcare institutions.
Bookmark this page for streamlined access to CNMD's evolving role in medical technology innovation. Regularly updated content supports informed analysis of the company's market position and long-term growth trajectory within the competitive healthcare solutions landscape.
CONMED reported Q4 2022 sales of $250.9 million, an 8.4% decline year-over-year, with domestic revenue down 3.9% and international revenue down 13.8%. Diluted net earnings per share (GAAP) rose 14.7% to $0.86, while adjusted earnings fell 60.7% to $0.42. For full-year 2022, sales grew 3.4% to $1,045.5 million. However, the company reported a diluted net loss per share of $2.68, contrasting with earnings of $1.94 in 2021. For 2023, CONMED forecasts revenue between $1.170 billion and $1.220 billion, with adjusted EPS expected at $3.20 to $3.45.
CONMED Corporation (NYSE: CNMD) is set to release its fourth quarter 2022 financial results on February 2, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the outcomes. Participants can pre-register for the call or access a live webcast on CONMED's website. The company specializes in surgical devices for minimally invasive procedures across various medical fields. The press release includes forward-looking statements regarding the impact of the COVID-19 pandemic on the business and operating volumes.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of
CONMED Corporation (NYSE: CNMD) announced participation in the 34th Annual Piper Sandler Healthcare Conference, with a fireside chat led by Curt R. Hartman and Todd W. Garner on November 30, 2022, at 3:30 p.m. ET. A live audio webcast will be available on the 'Investors' section of their website and will be replayed afterward. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery. For more details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) has withdrawn its full-year 2022 financial outlook due to unexpected shipping disruptions caused by new warehouse management software implementation. The backlog peaked at $35 million but has now decreased to $28 million. Despite these challenges, daily shipment volumes have returned to normal, and the company anticipates limited impact on fourth-quarter performance. For 2023, CNMD expects revenue between $1.170 billion and $1.230 billion, with adjusted diluted net earnings per share projected between $3.20 and $3.50.
CONMED Corporation (NYSE: CNMD) announced participation in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 1:15 p.m. ET. Key executives, including Curt R. Hartman, Chair and CEO, and Todd W. Garner, CFO, will represent the company. Interested parties can access a live audio webcast through the company’s website, which will also offer a replay after the event. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) reported a strong Q3 2022 with sales of $275.1 million, a 10.6% increase year-over-year. Domestic revenue surged by 14.2%, while international revenue grew 6.2%. Diluted net earnings per share rose to $1.48 from $0.47 a year prior, although adjusted diluted EPS fell 3.8% to $0.77. The company has narrowed its full-year revenue guidance to between $1.1 billion and $1.115 billion, reflecting a 150 to 180 bps negative impact from foreign exchange. The recent acquisition of Biorez is expected to contribute positively to revenue growth.
CONMED Corporation (NYSE: CNMD) will release its third-quarter 2022 financial results on October 26, 2022, post market close. A conference call to discuss the results will take place at 4:30 p.m. ET on the same day. Interested parties can participate via telephone by pre-registering online or access the webcast from CONMED's website, with a replay available after the call.
CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties.
CONMED Corporation (NYSE: CNMD) announced participation in the 20th Annual Morgan Stanley Global Healthcare Conference. The fireside chat featuring Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, CFO, is scheduled for September 13, 2022, at 5:15 p.m. ET. A live audio webcast will be accessible via the Company’s website, with a replay available post-event. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties. For more information, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2022, to shareholders on record as of September 15, 2022. This financial move reinforces the company's commitment to returning value to its shareholders. CONMED specializes in surgical devices and equipment for minimally invasive procedures across various medical specialties.
FAQ
What is the current stock price of Conmed (CNMD)?
What is the market cap of Conmed (CNMD)?
